EHA 2019 Archives - Medical Conferences

Home > Haematology > EHA 2019

Read the full Report (pdf)

European Hematology Association

13-16 June 2019 Amsterdam, the Netherlands

Introduction to the Conference Report of the EHA

Conference

EHA 2019

9 August 2019 23:23

Editor Biography

Editor

Prof. Gert Ossenkoppele, VU University Medical Center, Amsterdam, the Netherlands

Conference

EHA 2019

9 August 2019 11:53

Interview with EHA President Prof. Pieter Sonneveld

Expert

Prof. Pieter Sonneveld, Erasmus Medical Center in Rotterdam, the Netherlands

Conference

EHA 2019

9 August 2019 09:59

Online First

Myeloid Malignancies

Residual disease in AML patients prior to stem cell transplant increases relapse risk

Presented By

Dr Christopher Hourigan, NIH, USA

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 23:05

Gilteritinib prolongs overall survival in patients with FLT3-mutated relapsed/refractory AML

Presented By

Dr Alexander Perl, University of Pennsylvania, USA

Trial

Phase 3, ADMIRAL

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 22:14

Initial data on AMV564 in patients with relapsed/refractory AML

Presented By

Prof. Gail Roboz, Weill Cornell Medicine, USA

Trial

Phase 1, AMV564-101

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 21:18

Overcoming the “don’t eat me” signal in AML and MDS

Presented By

Dr David Sallman, Moffitt Cancer Center, USA

Trial

5F9005

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 20:20

Asciminib plus imatinib in patients with heavily pre-treated chronic myeloid leukaemia

Presented By

Prof. Jorge Cortes, University of Texas MD Anderson Cancer Center, USA

Trial

Phase 1

Conference

EHA 2020

Type

Peer-reviewed article

9 August 2019 12:22

Guadecitabine vs treatment of choice in AML

Presented By

Prof. Pierre Fenaux, Hôpital Saint-Louis, France

Trial

Phase 3, ASTRAL-1

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 09:25

Lymphoid Malignancies

Unmutated IGHV as predictive factor for venetoclax/obinutuzumab benefit in frontline CLL

Presented By

Dr Eugen Tausch, University of Ulm, Germany

Trial

CLL14

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 22:38

CAR-T cell therapy in ALL as breakthrough advance

Presented By

Prof. Mohamad Mohty, Saint-Antoine Hospital and University Pierre & Marie Curie, France

Trial

Phase 2, ELIANA

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 21:36

Brentuximab vedotin continues to demonstrate superior clinical activity in classical Hodgkin lymphoma

Presented By

Dr Steven Horwitz , Memorial Sloan Kettering Cancer Center, USA

Trial

Phase 3, ECHELON-1

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 20:49

Infectious complications mild and not common in patients receiving CAR-T therapy for diffuse large B cell lymphoma

Presented By

Dr Roberta Di Blasi, Hospital Saint-Louis, France

Trial

JULIET and ZUMA1

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 19:55

Obinutuzumab/polatuzumab in follicular lymphoma

Presented By

Prof. Wojciech Jurczak, Jagiellonian University, Poland

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 17:13

Exciting survival data for ibrutinib vs placebo in treatment-naïve, early-stage CLL

Presented By

Dr Petra Langerbeins, University of Cologne, Germany

Trial

Phase 3, CLL12

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 16:26

ASCEND study: Acalabrutinib improves progression-free survival in relapsed/refractory CLL

Presented By

Dr Paolo Ghia, Vita-Salute San Raffaele University, Italy

Trial

Phase 3, ASCEND

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 15:28

Venetoclax-obinutuzumab combination elicits high response rates in CLL

Presented By

Dr Kirsten Fischer, University of Cologne, Germany

Trial

Phase 3, CLL14

Conference

EHA 2019

Type

Peer-reviewed article

9 June 2019 23:28

Myeloma

CASSIOPEIA trial: Phase 3 results of daratumumab + bortezomib/thalidomide/dexamethasone in multiple myeloma

Presented By

Prof. Phillippe Moreau, University Hospital of Nantes, France

Trial

Phase 3, CASSIOPEIA

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 23:30

Chimeric antigen receptor T cell therapy in multiple myeloma

Presented By

Prof. Hermann Einsele, University of Würzburg, Germany

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 22:34

Higher levels of treatment satisfaction without compromising efficacy: subcutaneous daratumumab in RRMM

Presented By

Prof. María-Victoria Mateos , University of Salamanca, Spain

Trial

Phase 3, COLUMBA

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 21:36

Adding isatuximab to pomalidomide and dexamethasone improves PFS and ORR in RRMM

Presented By

Prof. Michel Attal, University Institute Cancer Toulouse Oncopole, France

Trial

Phase 3, ICARIA-MM

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 20:38

Subcutaneous daratumumab + cyclophosphamide, bortezomib, and dexamethasone in patients with newly diagnosed amyloid light chain amyloidosis

Presented By

Prof. Raymond Comenzo, Tufts University, USA

Trial

Phase 3, ANDROMEDA

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 19:40

Venetoclax for multiple myeloma: effective but some safety concerns

Presented By

Dr Shaji Kumar, Mayo Clinic, USA

Trial

Phase 3, BELLINI

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 09:42

Benign Haematology

New sickle cell drug voxelotor boosts levels of haemoglobin

Presented By

Dr Jo Howard, King’s College London, United Kingdom

Trial

Phase 3, HOPE

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 23:49

Positive initial data evaluating the safety and efficacy of IMR-687 for treatment of sickle cell disease

Presented By

Dr Biree Andemariam, UConn Health, USA

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 22:50

Haematopoietic stem cell transplantation improves stroke risk in children with sickle cell anaemia

Presented By

Dr Francoise Bernaudin, Intercommunal Hospital Center de Créteil, France

Trial

DREPAGREFFE

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 21:52

Early trial data shows positive results for treating anaemia in patients with end-stage renal failure

Presented By

Prof. Lutz Renders, Klinikum Rechts der Isar, Germany

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 19:54

Bench-to-Bedside

Transformation of foetal haematopoietic stem and progenitor cells in the background of trisomy 21

Presented By

Dr Sophia Gialesaki, Hannover Medical School, Germany

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 23:00

Treating thalassemia twice, in mice

Presented By

Dr Antonella Nai, San Raffaele Scientific Institute, Italy

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 22:03

Haematopoietic stem cells can sense tissue damage in the gut

Presented By

Dr Hitoshi Takizawa, Kumamoto University, Japan

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 20:19

Promising news for gene therapy for sickle cell disease

Presented By

Dr Olivier Hermine, Necker Hospital, France

Trial

Phase 1/2, HGB-206

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 08:25

Featured articles

CONTENTS

Online First

Myeloid Malignancies

Lymphoid Malignancies

Myeloma

Benign Haematology

Bench-to-Bedside